Adult brainstem glioma

• Fusion of glioma-associated mesenchymal stem/stromal cells with glioma cells promotes macrophage recruitment and M2 polarization via m(6)A modification of CSF1
• Characteristics and outcomes of diffuse non-midline gliomas with H3F3A gene mutation in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort study
• Dyr726, a brain-penetrant inhibitor of PI3Kalpha, Type III receptor tyrosine kinases, and WNT signaling
• Case Report: Rare intraventricular H3 K27-altered diffuse midline glioma in an adult
• The m6A RNA demethylase FTO promotes radioresistance and stemness maintenance of glioma stem cells
• Generation and validation of a novel multitarget small molecule in glioblastoma
• In vitro investigation of epigenetic regulators related to chemo-resistance and stemness of CD133^+VE cells sorted from U87MG cell line
• Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults

Brainstem gliomas are uncommon in adults and account for only 1%-2% of intracranial gliomas. They represent a heterogeneous group of tumors that differ from those found in their pediatric counterparts. In adults, a low-grade phenotype predominates, which is a feature that likely explains their better prognosis compared to that in children ¹⁾.

Adult brainstem glioma classification.

Adult brainstem glioma treatment

A 32-year-old man presented with left facial numbness and right hemiparesis and was referred to our department. MRI and open biopsy indicated brainstem glioma, and he was specifically diagnosed with isocitrate dehydrogenase 1-mutant diffuse astrocytoma of WHO grade II. He was treated with stereotactic radiotherapy followed by autologous formalin-fixed tumor vaccine (AFTV) three months later. MRI conducted at 42 months after the combination therapy showed a 91% decrease in tumor volume, and the regression was maintained for 5 years. Thus, combination treatment with radiotherapy and immunotherapy may prove to be a promising alternative for the treatment of brainstem glioma ²⁾.